Literature DB >> 16048988

In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.

Annie Philip1, Zekaver Odabasi, Jose Rodriguez, Victor L Paetznick, Enuo Chen, John H Rex, Luis Ostrosky-Zeichner.   

Abstract

The in vitro interactions of anidulafungin with itraconazole, voriconazole, and amphotericin B were evaluated by using the checkerboard method. For Aspergillus spp., anidulafungin with amphotericin B showed indifference for 16/26 isolates, while anidulafungin with either azole showed a synergy trend for 18/26 isolates. All drug combinations showed indifference for 7/7 Fusarium sp. isolates.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048988      PMCID： PMC1196215          DOI： 10.1128/AAC.49.8.3572-3574.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Introduction to antifungal drugs.

Authors:  W E Dismukes
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

Review 2.  Systemic mycoses in the immunocompromised host: an update in antifungal therapy.

Authors:  D P Kontoyiannis; E Mantadakis; G Samonis
Journal:  J Hosp Infect       Date:  2003-04       Impact factor: 3.926

3.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

4.  Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice.

Authors:  H EAGLE
Journal:  Am J Med       Date:  1952-10       Impact factor: 4.965

Review 5.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

6.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Authors:  Johan Maertens; Issam Raad; George Petrikkos; Marc Boogaerts; Dominik Selleslag; Finn B Petersen; Carole A Sable; Nicholas A Kartsonis; Angela Ngai; Arlene Taylor; Thomas F Patterson; David W Denning; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

7.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

8.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

Authors:  D A Stevens; V L Kan; M A Judson; V A Morrison; S Dummer; D W Denning; J E Bennett; T J Walsh; T F Patterson; G A Pankey
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

9.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 10.  The first echinocandin: caspofungin.

Authors:  O A Cornely; Karina Schmitz; Sabine Aisenbrey
Journal:  Mycoses       Date:  2002       Impact factor: 4.377
View more
  21 in total

1.  In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.

Authors:  Virginie Planche; Sebastien Ducroz; Alexandre Alanio; Marie-Elisabeth Bougnoux; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  In vitro interaction between fluconazole and triclosan against clinical isolates of fluconazole-resistant Candida albicans determined by different methods.

Authors:  Lu Yu; Guanghui Ling; Xuming Deng; Jing Jin; Qi Jin; Na Guo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Current role of echinocandins in the management of invasive aspergillosis.

Authors:  Małgorzata Mikulska; Claudio Viscoli
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

4.  Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

Authors:  Enrique Calvo; F Javier Pastor; Valentina Salas; Emilio Mayayo; Josep Guarro
Journal:  Mycopathologia       Date:  2011-12-04       Impact factor: 2.574

5.  In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Authors:  A Raffetin; V Courbin; V Jullien; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

6.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

7.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

8.  Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.

Authors:  Susanne Perkhofer; Daniel Jost; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

Review 9.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex.

Authors:  Kerry O'Donnell; Deanna A Sutton; Annette Fothergill; Dora McCarthy; Michael G Rinaldi; Mary E Brandt; Ning Zhang; David M Geiser
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.